Randomized,Double Blind,Placebo-Controlled Clinical Trial to Evaluate the Lymphagogue Effect and Clinical Efficacy of Calcium Dobesilate in Chronic Venous Disease

Abstract

The aims of the present study were to investigate the effect of calcium dobesilate on lymph flow and lymphovenous edema in patients with chronic venous disease. It was a randomized, placebo-controlled, double-blind clinical trial. Patients received 1 capsule of 500 mg calcium dobesilate every 8 hours (1.5 g/day) or placebo by 49 days. By the end of the treatment period, only the patients treated with calcium dobesilate had normalization of lymphogammagraphy (capture index and speed of lymph flow; 80 and 78%, respectively). Only patients treated with calcium dobesilate had statistically significant reduction in the perimeter of leg, calf, and ankle. Twenty-two out of 25 (88%) calcium dobesilate—treated patients presented clinical improvement versus 5 out of 24 (20.8%) in the placebo group. One patient on calcium dobesilate developed rash and one patient on placebo complained of vomiting. In the present study, calcium dobesilate normalized lymph physiology and improved symptoms in patients with chronic venous disease.

Keywords

chronic venous disease calcium dobesilate lymph edema lymphogammagraphy

Get full access to this article

View all access options for this article.

References

Nicolaides AN Cardiovascular Disease Educational and Research Trust; European Society of Vascular Surgery; the International Angiology Scientific Activity Congress Organization; International Union of Angiology; Union Internationale de Phlebologie at the Abbaye des Vaux de Cernay. Investigation of chronic venous insufficiency: a consensus statement (France, March 5-9, 1997). Circulation. 2000;102:E126-E163.

Beebe-Dimmer JL , Pfeifer JR , Engle JS , Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005;15:175-184.

Brand FN , Dannenberg AL , Abbott RD , Kannel WB The epidemiology of varicose veins: the Framingham Study. Am J Prev Med. 1988;4:96-101.

Hume M. A venous renaissance? J Vasc Surg. 1992;15: 947-951.

Ramelet AA , Boisseau MR , Allegra C. , et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc. 2005;33:309-319.

Martinez MJ , Bonfill X. , Moreno RM , Vargas E. , Capellà D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005;(3):CD003229, doi:10.1002/14651858 .CD003229.

Garay RP , Hannaert P. , Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol. 2005;4:221-232.

Tejerina T. , Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol. 1998;31:357-360.

Brunet J. , Farine JC , Garay RP , Hannaert P. Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Eur J Pharmacol. 1998;358:213-220.

10.

Suschek C. , Kolb H. , Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol. 1997;122:1502-1508.

11.

Falkay G. , Kovacs L. Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro. Experientia. 1984 ;40:190-191.

12.

Casley-Smith JR , Casley-Smith JR The effects of calcium dobesilate on acute lymphedema (with and without macrophages), and on burn edema. Lymphology. 1985;18:37-45.

13.

Casley-Smith JR The influence of tissue hydrostatic pressure and protein concentration on fluid and protein uptake by diaphragmatic initial lymphatics; effect of calcium dobesilate. Microcirc Endothelium Lymphatics. 1985;2:385-415.

14.

Piller NB The lymphogogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology . 1988;21:124-127.

15.

Lameynardie S. , Chiavaroli C. , Travo P. , Garay RP , Parés-Herbuté N. Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats. Eur J Pharmacol . 2005;510:149-156.

16.

Rota R. , Chiavaroli C. , Garay RP , Hannaert P. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol. 2004; 495:217-224.

17.

Widmer L. , Biland L. , Barras JP Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. Int Angiol. 1990;9:105-110.

18.

Pecchi S. , De Franco V. , Damiani P. , Guerrini M. , Di Perri T. Calcium dobesilate in the treatment of primary venous insufficiency of the lower limbs. A double-blind clinical study. Clin Ter. 1990;132:409-417.

19.

Jaeger K. , the CVI Study Group. Efficacy and safety of doxium in chronic venous insufficiency: double-blind, placebo-controlled multicentre study. Int Angiol. 2001; 20 (Suppl 1):239.

20.

Allain H. , Ramelet AA , Polard E. , Bentue-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf. 2004; 27:649-660.

21.

Widmer LK Peripheral Venous Disorders. Prevalence and Sociomedical Importance. Basel Study III. Bern, Switzerland: Hans Huber; 1978.

22.

Espinosa JD , Giannone CA Tratamiento de la insuficiencia venosa cronica con dobesilato de calcio. Un meta-analisis. Flebologia. 2001;1:15-20.